{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.0","upperLimit":"48.7","value":"36.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants whose BOR was CR, clinical complete response (CCR) or PR per IRC. The tumor response was based on Prince 2010 criteria. CR was defined as disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. CCR was defined as tumor residue not visible on esophagogram, computed tomography (CT), endoscopy, positron emission tomography (PET)-CT.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with stages I to III CTCL were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG000","title":"Main Study Part: E7777 9 mcg/kg"}],"paramType":"NUMBER","populationDescription":"Primary efficacy analysis set included all participants with Stages I to III CTCL (both Main Study and Lead-In part) who received study drug at the 9 mcg/kg dose.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until disease progression (Up to 3 years 6 months)","title":"Main Study Part: ORR Per IRC Based on Prince 2010 Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}